ARTL
NASDAQ · Pharmaceuticals
Artelo Biosciences Inc
$5.34
-0.45 (-7.77%)
Financial Highlights (FY 2025)
Revenue
653.2K
Net Income
176.4K
Gross Margin
65.9%
Profit Margin
27.0%
Rev Growth
-7.3%
D/E Ratio
0.34
Revenue & Net Income
Margin Trends
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Gross Margin | 65.9% | 65.9% | 65.9% |
| Operating Margin | 30.6% | 26.9% | 31.1% |
| Profit Margin | 27.0% | 27.4% | 26.5% |
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 653.2K | 640.4K | 651.1K |
| Gross Profit | 430.2K | 421.8K | 428.8K |
| Operating Income | 199.8K | 172.1K | 202.3K |
| Net Income | 176.4K | 175.3K | 172.4K |
| Gross Margin | 65.9% | 65.9% | 65.9% |
| Operating Margin | 30.6% | 26.9% | 31.1% |
| Profit Margin | 27.0% | 27.4% | 26.5% |
| Rev Growth | -7.3% | -5.3% | +22.2% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 396.9K | 353.4K | 397.0K |
| Total Equity | 1.18M | 1.18M | 1.24M |
| D/E Ratio | 0.34 | 0.30 | 0.32 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 261.8K | 256.2K | 270.8K |
| Free Cash Flow | 66.8K | 83.8K | 75.0K |